Rhinomed Stock Forecast, Price & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume452,773 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

Receive RNO News and Ratings via Email

Sign-up to receive the latest news and ratings for Rhinomed and its competitors with MarketBeat's FREE daily newsletter.

About Rhinomed

Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide. It identifies, acquires, and commercializes nasal stent delivery technologies. The company's product portfolio includes Turbine for enhanced breathing in sports; Mute, an anti-snoring device; and Pronto for nasal congestion and sleep disturbance issues. It also engages in developing applications for the delivery of medical cannabis and conditions, including anxiety, pain, allergies, nausea, anxiety, and coughs and colds; and nasal swab to test the presence of upper respiratory tract diseases, including influenza, and coronavirus strains. The company was formerly known as Consegna Group Limited and changed its name to Rhinomed Limited in November 2013. Rhinomed Limited was incorporated in 2004 and is based in Richmond, Australia.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.27 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Rhinomed (ASX:RNO) Frequently Asked Questions

What stocks does MarketBeat like better than Rhinomed?

Wall Street analysts have given Rhinomed a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Rhinomed wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Rhinomed's earnings last quarter?

Rhinomed Limited (ASX:RNO) released its quarterly earnings data on Thursday, February, 28th. The company reported ($0.02) EPS for the quarter.
View Rhinomed's earnings history

Who are Rhinomed's key executives?

Rhinomed's management team includes the following people:
  • Mr. Michael Johnson, CEO, MD & Exec. Director
  • Mr. Sean Slattery, CFO & Company Sec.

Who are some of Rhinomed's key competitors?

What is Rhinomed's stock symbol?

Rhinomed trades on the ASX under the ticker symbol "RNO."

How much money does Rhinomed make?

Rhinomed has a market capitalization of $0.00 and generates $4.65 million in revenue each year.

What is Rhinomed's official website?

The official website for Rhinomed is

Where are Rhinomed's headquarters?

Rhinomed is headquartered at 97 Green St, RICHMOND, VIC 3121, Australia.

How can I contact Rhinomed?

Rhinomed's mailing address is 97 Green St, RICHMOND, VIC 3121, Australia. The company can be reached via phone at +61-3-84160900.

This page was last updated on 9/20/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.